[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-constipation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-constipation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,79,101,119,150,172,197,224],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100629357","outcome-research-in-bowel-irrigation-techniques-for-the-treatment-of-chronic-constipation-andor-faecal-incontinence-100629357",false,"NCT07473622","Outcome Research in Bowel Irrigation Techniques for the Treatment of Chronic Constipation and\u002For Faecal Incontinence","Outcome Research in Bowel Irrigation Techniques: A Novel Self-retaining Catheter Compared With a Conventional Balloon Catheter for the Treatment of Chronic Constipation and\u002For Faecal Incontinence, a Real-world Randomised Explorative Investigation.","ORBIT-1","Inclusion Criteria:\n\n* Faecal incontinence (FI), chronic constipation (CC) or co-existing FI\u002FCC, all of heterogenous origin\n* Positive Rome IV criteria for functional constipation and\u002For positive Rome IV criteria for faecal incontinence\n* 18 years or older\n* Ability to understand written and spoken English (due to questionnaire validity)\n* Ability to understand and provide written, informed consent prior to any investigation-specific procedures\n\nExclusion Criteria:\n\n* Prior use of transanal irrigation\n* Neurogenic bowel dysfunction\n* Low anterior resection syndrome (this group will be excluded due to the possibility of being randomised to a balloon catheter).\n* Previous rectal and\u002For anal surgery (except minor rectal or anal surgery such as haemorrhoid procedures, anal fissure surgery, drainage of a perianal\u002Frectal abscess, or other rectal or anal surgeries deemed minor by the investigator)\n* Physical disability that affects the ability to independently use the irrigation device\n* Intermittent use of opioids inducing chronic constipation\n* Patulous anus\n* Participation in research conflicting with the current investigation\n* Physical or mental conditions affecting the ability to comply with the clinical investigation plan\n* Pregnancy or plans to become pregnant during the investigation period","ALL","18 Years",{"count":20,"type":21},66,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical investigation is a post-market, exploratory, randomised, parallel, open-label investigation comparing two UKCA\u002FCE-marked transanal irrigation products for the management of faecal incontinence and\u002For chronic constipation of heterogenous origin. The aim of this investigation is to assess outcomes in a real-world clinical setting, by following the typical clinical routine, with randomisation and more frequent visits\u002Fphone calls as the only difference from typical clinical procedure.\n\nDuring 4-week training period, participants will trained by nurse specialists on how to use the device to which they were randomised to and will be instructed to irrigate once per day. For the remainder of the investigation, participants will be advised to continue irrigation once daily (or a minimum of 3 times a week). Participants will be followed up via phone call or in-person visit up to 52 weeks.",[27,28],"Faecal Incontinence","Chronic Constipation","NOT_YET_RECRUITING","2026-03-10",{"date":32,"type":33},"2026-03-16","ACTUAL",{"date":35,"type":21},"2026-08-01",{"date":37,"type":21},"2028-02",{"name":39,"class":40},"Qufora A\u002FS","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100626155","phase-4-efficacy-and-safety-of-linaclotide-in-chronic-constipation-100626155","NCT07431957","\"Efficacy and Safety of Linaclotide in Chronic Constipation\"","\"Efficacy and Safety of Linaclotide in Chronic Constipation : A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study\"","LIN-CC-BD","Inclusion Criteria:\n\n* Adult patients (18-70 years)\n* patients diagnosed with CIC or IBS-C based on Rome IV criteria\n* No abnormal finding on colonoscopy conducted within past 1 year\n* Patients who can read and are willing to complete daily bowel diary and follow study procedures\n\nExclusion Criteria:\n\n* Clinical features suggestive of organic disease ( Anaemia, unexplained weight loss, per rectal bleeding, family history of malignancy)\n* Secondary constipation due to structural, metabolic, or neurological causes (IBD, Colorectal cancer, hypothyroidism, hypercalcemia, DM, Parkinson's disease)\n* History of or new onset intestinal obstruction\n* Prior history of stomach, small intestine and colorectal surgery ( except appendectomy or hemorroidectomy)\n* Patients currently suffering from medication induced costipation ( opioids, anti choline raids, calcium channel blockers, oral iron and calcium supplements, anti-Parkinsonian drug, antipsychotic, anti-emetics or psychostimulant drugs)\n* Use of medication affecting bowel motility ( Lubiprostone, Elobixibat, PEG or prosecretory agents) within 2 week before enrollment\n* Serious cardiovascular, respiratory, renal, GI, hepatic, hematological, neurological or psychiatric illness\n* Pregnancy or lactation","70 Years",{"count":51,"type":21},90,[53],"PHASE4","Goal of this study is to evaluate the efficacy and safety of two different doses of Linaclotide in improving bowel function and patient-reported outcomes among Bangladeshi patients with chronic constipation for 8 weeks along with an additional short drug-free follow up period of 2 weeks. The main question it aims to answer is \"Does Linaclotide at doses of 72microgram or 145microgram once daily improve bowel function and patient-reported coutcomes compared with placebo in Bangladeshi patients with chronic constipation over an 8-week treatment period?\"\n\nStudy procedure:\n\nFrom outpatient department of Gastroenterology, Dhaka Medical College, a total of 90 adult patients diagnosed with chronic idiopathic constipation (CIC) or constipation predominant irritable bowel syndrome (IBS-C) by ROME-IV criteria will be selected after baseline evaluation including clinical history, physical examination, laboratory tests and colonoscopy. Before enrollment eligible participants will undergo 1-week baseline stool diary which will include baseline data of patient reported severity of abdominal symptoms (bowel movement, stool frequency, bloating, abdominal pain or discomfort and defecatory satisfaction score). Patients reporting more than 3 SBMs during baseline run in period will be excluded from the study. Finally total 90 patients will be enrolled as participants who will be randomly assigned to one of the three groups, Group A (Linaclotide 72mcg once daily), Group B (Linaclotide 145mcg once daily) and Group C (Placebo once daily ). The treatment period will start from randomization visit (day 0) and will be continued for 8 weeks. All participants will receive identical looking drugs (72mcg or 145mcg or placebo) 30 minutes before breakfast and they will be requested to maintain standard dietary and lifestyle advices including increased intake of high fiber diet and fluid throughout the study. Patients will record spontaneous bowel movement (SBM) and complete spontaneous bowel movement (CSBM), stool consistency using Bristol Stool Form Scale (BSFS), severity of abdominal symptoms by 5-point Likert scale, use of rescue medication after 3 days of absolute constipation and adverse events such as diarrhea in their daily stool diary. They will be followed up at week-4, week-8 and after 2-week drug free withdrawal period at week-10 with review of stool diary and safety assessments. Entire study will be monitored by Data Safety Monitoring Board (DSMB) of Dhaka Medical College.",[56,57,28,58,59],"Chronic Idiopathic Constipation","Irritable Bowel Syndrome (IBS-C)","CIC","Constipation Predominant Irritable Bowel Syndrome",[61,58,62,63,64,65,66,47,67,57],"CC","IBS-C","Chronic Constipation (CC)","Chronic Idiopathic Constipation (CIC)","Constipation predominant Irritable Bowel Syndrome (IBS-C)","Linaclotide","Linaclotide RCT","2026-02-21",{"date":70,"type":33},"2026-02-25",{"date":72,"type":21},"2026-02-20",{"date":74,"type":21},"2027-01-31",{"name":76,"class":77},"Md Mehedi Shahriar","OTHER",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":78},"100622682","the-efficacy-and-safety-of-microbiota-transplantation-combined-with-prebiotics-for-treatment-of-functional-constipation-100622682","NCT07386795","The Efficacy and Safety of Microbiota Transplantation Combined With Prebiotics for Treatment of Functional Constipation","Inclusion Criteria:\n\n* Diagnosed with functional constipation (FC) according to Rome IV criteria.\n* Symptoms persisting for at least 6 months, with criteria met for the last 3 months.\n* Ineffective response to traditional treatments (dietary intervention, at least 2 types of laxatives, or probiotics).\n* Willing to discontinue other constipation medications, herbal medicines, or supplements during the study.\n\nExclusion Criteria:\n\n* History or clinical evidence of mechanical bowel obstruction (e.g., tumor or hernia).\n* Diagnosis of megarectum, megacolon, or pseudo-obstruction.\n* Organic intestinal abnormalities (obstruction, stenosis, cancer) or inflammatory bowel disease (IBD).\n* Progressive colorectal polyps requiring treatment.\n* History of gastrointestinal or abdominal surgery within the past 3 months.\n* Severe cardiovascular or cerebrovascular diseases.\n* Clinically significant liver function abnormalities (ALT\u002FAST \\> 2x ULN, TBIL ≥ 1.5x ULN).\n* Pregnancy, lactation, or planning to conceive during the study.\n* Inability to undergo colonoscopy or catheter placement.\n* Participation in other clinical trials within the past 3 months.\n* Other health conditions deemed unsuitable by the investigator.",{"count":86,"type":21},19,[24],"Chronic constipation is a common gastrointestinal disorder with a global prevalence of approximately 15%, severely impacting daily life and quality of life. It also increases the mortality rate from hypertension, cardiovascular diseases, and ischemic stroke, and is closely related to the incidence of colorectal cancer, making it a major chronic disease that seriously threatens people's health and quality of life. With the increasing aging population and lifestyle factors such as sedentary behavior and low-fiber diets, the incidence of functional constipation is gradually rising. Traditional treatment of chronic constipation mainly relies on various types of laxatives, which have significant side effects with long-term use and relatively high treatment costs, while surgical treatment has limited patient acceptance. Gut microbiota is closely related to intestinal motility, and patients with chronic constipation often have gut microbiota dysbiosis, with significant differences in gut microbiota diversity and colonic mucosal microbiota structure compared to healthy individuals. In recent years, more and more studies have found that intestinal microbiota-based therapies such as probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT) can effectively prevent and treat chronic constipation. FMT, as a method to reshape the gut microbiota, has been widely used in many centers at home and abroad, for diseases including inflammatory bowel disease, irritable bowel syndrome, autism, and obesity. The overall adverse reaction rate in clinical applications is approximately 3%, mainly consisting of abdominal discomfort (bloating, abdominal pain), diarrhea, and secondary intestinal infections or even bacteremia (rare). Our center has established a fecal microbiota transplantation center at Beijing Sixth Hospital within our medical alliance. We have currently performed nearly 100 cases of FMT for the treatment of IBD, autism, functional bowel diseases, and other metabolic diseases, with a clinical efficacy rate of 64-85% for functional constipation and constipation-predominant irritable bowel syndrome. This project aims to validate an intervention strategy combining fecal microbiota transplantation (FMT) with prebiotics primarily composed of high dietary fiber, based on the theoretical framework developed by the team led by Diwei Zheng at the Institute of Process Engineering, Chinese Academy of Sciences.The team found that the core microbiota playing a major role in the FMT process determines the therapeutic efficacy of FMT on diseases.These core microbial communities can produce acetic acid and butyric acid, which are important metabolites that not only reduce inflammatory levels and improve intestinal barrier function, but also provide energy for intestinal epithelial cells. Additionally, they effectively limit the growth of opportunistic pathogens by acidifying the intestinal environment, exerting antibacterial effects, and utilizing niche effects.Therefore, when the core microbiota occupies a dominant ecological niche in the gut, the gut microbiota can support health from multiple aspects including nutrition, immunity, metabolism, and psychology. Prebiotics designed based on the characteristics of the core microbiota can significantly enhance the activity and colonization of the core microbiota.This study aims to reconstruct a healthy intestinal ecosystem through FMT and prebiotics. Simultaneously, it proposes a \"co-localization\" strategy, which involves physically mixing prebiotics with core microbiota during transplantation to coexist synergistically. This approach enhances the metabolic function of core microbiota more efficiently locally, promotes the production of key metabolites such as acetic acid and butyric acid, and improves the intestinal microenvironment.Compared with the traditional stepwise model of 'microbiota transplantation + prebiotic intervention', this approach can significantly reduce the dosage of prebiotics, thereby further enhancing the safety and tolerability of the intervention.This clinical study is designed as an open-label, single-arm trial, aiming to enroll 19 patients with refractory functional constipation to receive \"core microbiota transplantation based on co-localization\".The study will focus on evaluating the therapeutic efficacy of the treatment in improving constipation symptoms, systematically assessing its safety, and comprehensively evaluating the level of gut microbiota remodeling through microbiome and metabolome approaches.The implementation of this project will provide clinical evidence for exploring the application of core microbiota therapy in functional bowel disorders such as constipation, and lay the foundation for optimizing and promoting microecological intervention strategies.",[90,28,91],"Constipation - Functional","Fecal Microbiota Transplantation","2026-01-27",{"date":94,"type":33},"2026-02-04",{"date":96,"type":21},"2026-02-01",{"date":98,"type":21},"2026-12-31",{"name":100,"class":77},"Peking Union Medical College Hospital",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":118,"locationsCount":78},"100622771","the-safety-and-efficacy-of-fecal-microbiota-transplantation-combined-with-nutritional-intervention-in-the-treatment-of-functional-constipationa-pilot-study-100622771","NCT07387952","The Safety and Efficacy of Fecal Microbiota Transplantation Combined With Nutritional Intervention in the Treatment of Functional Constipation：a Pilot Study","Inclusion Criteria:\n\n1. Age: 18 to 70.\n2. Diagnostic criteria: Functional constipation (FC) in accordance with Rome IV criteria, which should meet the following conditions:\n\n   * Symptom requirements: The following at least 2 items should occur in ≥25% of bowel movements: a. Straining during defecation; b. Hard stool (Bristol Stool Classification score 1-2); c. Feeling of incomplete evacuation; d. Rectal obstruction sensation; e. Need for finger assistance during defecation; f. Spontaneous bowel movements \\\u003C3 times per week.\n   * It is rare to have loose stools without laxatives.\n   * Exclusion of irritable bowel syndrome (IBS): IBS diagnosis criteria not meeting Rome IV.\n   * Disease course requirements: Symptoms persist for at least 6 months and meet the above criteria within the last 3 months.\n3. Traditional treatment methods (dietary intervention, at least two laxatives or probiotics) are ineffective.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation.\n2. Unable to take the intervention product or complete the examination as required.\n3. Language expression disorder or mental illness.\n4. Physical examination showed severe liver and kidney dysfunction.\n5. Acute gastrointestinal disease within 4 weeks.\n6. Constipation caused by surgery in the past 4 weeks.\n7. History or abnormal examination: cancer, severe enteritis, intestinal obstruction, inflammatory bowel disease, hypothyroidism, mental illness, stroke, heart disease, cirrhosis, renal failure, hematopoietic system diseases, organic bowel disease suggested by colonoscopy or imaging.\n8. Participation in other clinical trials within 3 months prior to enrollment.\n9. Other health problems are not suitable for participation in the study.",{"count":108,"type":21},5,[24],"Chronic constipation is a common gastrointestinal disease with a global prevalence of about 15%, significantly affecting daily life and quality of life. Traditional treatments primarily rely on laxatives, which may lead to adverse effects with prolonged use, while surgical interventions have limited patient acceptance. Recent studies indicate that gut microbiota therapies-including probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT)-can effectively manage chronic constipation. This study aims to investigate the safety and efficacy of FMT combined with a prebiotic nutritional intervention (using a co-localization strategy) in the treatment of functional constipation. Additionally, the investigators will explore changes in fecal microbiota and metabolomic profiles following the treatment.",[90,112,28],"Fecal Microbiota Transplantation (FMT)","RECRUITING",{"date":94,"type":33},{"date":116,"type":33},"2025-07-30",{"date":98,"type":21},{"name":100,"class":77},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":126,"sex":17,"minAge":127,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":78},"100586159","msot-and-mri-for-non-invasive-assessment-of-intestinal-transit-time-in-children-with-chronic-bowel-emptying-disorders-100586159","NCT06911749","MSOT and MRI for Non-invasive Assessment of Intestinal Transit Time in Children With Chronic Bowel Emptying Disorders","Contrast Enhanced Multispectral Optoacoustic Tomography and MRI for Non-invasive Assessment of Intestinal Transit Time in Children With Chronic Bowel Emptying Disorders","Inclusion Criteria:\n\nPatient Group\n\n* Written informed consent from the participant (starting at age 6).\n* Written informed consent from the legal guardian(s).\n* Suspected or confirmed diagnosis of chronic defecation disorder.\n* Age ≤ 18 years.\n* Willingness and ability to participate, with sufficient German language skills to understand the informed consent document.\n\nControl Group\n\n* Written informed consent from the participant.\n* Age \\> 18 years.\n* BMI \\\u003C 25 or medical suitability for MSOT examination as assessed by a physician.\n* Willingness and ability to participate, with sufficient German language skills to understand the informed consent document.\n\nExclusion Criteria:\n\n* Age \\\u003C 1 year.\n* Pregnancy or breastfeeding.\n* Tattoos in the examination area.\n* Subcutaneous fat tissue thickness \\> 3 cm.\n* Known hypersensitivity to ICG, sodium iodide, or iodine.\n* Thyroid dysfunction, including hyperthyroidism or focal\u002Fdiffuse thyroid autonomy.\n* Recent thyroid function testing with radioactive iodine treatment (within two weeks before or after the study).\n* Impaired renal function.\n* Use of specific medications, including:\n\n  * Beta-blockers,\n  * Anticonvulsants,\n  * Cyclopropane,\n  * Bisulfite compounds,\n  * Haloperidol,\n  * Heroin,\n  * Meperidine,\n  * Metamizole,\n  * Methadone,\n  * Morphine,\n  * Nitrofurantoin,\n  * Opium alkaloids,\n  * Phenobarbital,\n  * Phenylbutazone,\n  * Probenecid,\n  * Rifamycin,\n  * Any injection containing sodium bisulfite.\n* General contraindications for MRI, such as electrical implants (e.g., pacemakers, perfusion pumps).\n* Severe claustrophobia preventing MRI examination.",true,"1 Year",{"count":129,"type":21},20,[24],"The project presented here is a monocentric clinical study conducted by the Pediatric Surgery and Pediatrics departments of the University Hospital Erlangen. The study aims to experimentally expand the diagnostic approach for patients aged 0-17 years suffering from chronic bowel emptying disorders, regardless of any underlying causal or previously treated conditions.\n\nAt the core of this clinical study is the application of Multispectral Optoacoustic Tomography (MSOT) in combination with the oral contrast agent Indocyanine Green (ICG) to measure gastrointestinal transit time in children. Unlike conventional X-ray diagnostics, MSOT is radiation-free and considered non-invasive, although it has not yet been standardized for routine clinical use. Additionally, a contrast-free, non-invasive MRI technique will be employed to assess the peristalsis of intestinal segments.\n\nThe study aims to standardize the collection and evaluation of patient data following the administration of ICG and subsequent measurements using MSOT and MRI. The objective is to assess gastrointestinal transit time and peristalsis and, ultimately, to optimize therapy for affected patients. This is of particular importance in the coloproctology specialist consultation within the Pediatric Surgery and Pediatrics departments, as follows:\n\nIt enables differentiation between patients with slow transit constipation and outlet obstruction.\n\nIt allows for a more targeted application and evaluation of neuromodulation therapy, which is used within clinical studies.\n\nThis approach allows for the identification of specific intestinal segments with delayed transit time, enabling targeted electrical stimulation of these regions.\n\nA control group of healthy adult volunteers will participate in the study on a voluntary basis.",[28,133,134,135],"Slow Transit Constipation","Intestinal Transit Disorder","Hirschsprungs Disease",[137,138,139,140,135],"slow transit constipation","MSOT","ICG","gastrointestinal transit","2025-08-31",{"date":143,"type":33},"2025-09-03",{"date":145,"type":33},"2025-04-15",{"date":147,"type":21},"2026-06-01",{"name":149,"class":77},"Dr. med. Sonja Diez",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":126,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":78},"100581254","exploring-the-potential-benefits-of-probiotic-yogurt-100581254","NCT06847919","Exploring the Potential Benefits of Probiotic Yogurt","Exploring the Potential Benefits of High-activity Probiotic Yogurt: a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Meet the Rome IV diagnosis criteria for chronic constipation;\n2. Patients who are able to understand clinical studies and are committed to complying with study requirements and procedures;\n3. Age 18-65. -\n\nExclusion Criteria:\n\n1. Systemic (diabetes, autoimmune diseases, cancer), gastrointestinal or liver diseases known to be associated with alterations in the gut microbiota;\n2. Patients who are pregnant or lactating;\n3. have taken antimicrobials, probiotics, or drugs that inhibit stomach acid or gastrointestinal motility in the past 6 weeks;\n4. Patients who changed their diet type during the study;\n5. Patients who are allergic or intolerant to any component of the investigational product formulation;\n6. Patients with cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and other serious diseases and endocrine diseases, mental patients;\n7. Stop taking the tested sample or add other drugs in the middle, unable to judge the efficacy or incomplete data;\n8. short-term use of objects related to the function of the test, affecting the judgment of the result;\n9. have been dieting, exercising excessively, taking weight loss medications or taking medications that may affect appetite in the past 3 months;\n10. Current or past excessive use of alcohol, drugs, or supplements that may cause intestinal dysfunction or interfere with the evaluation of the efficacy of the study product -","65 Years",{"count":159,"type":21},84,[24],"This study aims to evaluate the effect of a high-activity probiotic yogurt on improving symptoms of chronic constipation, observing its regulatory effects on the gut microbiota and the incidence of adverse reactions in study participants over a 21-day intervention period.",[28],"2025-03-02",{"date":165,"type":33},"2025-03-05",{"date":167,"type":21},"2025-02-25",{"date":169,"type":21},"2025-12-30",{"name":171,"class":40},"Wecare Probiotics Co., Ltd.",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":179,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":78},"100557889","phase-1-anorectal-manometery-in-pediatric-chronic-refractory-constipation-100557889","NCT06543979","Anorectal Manometery in Pediatric Chronic Refractory Constipation","The Diagnostic Value of Anorectal Manometry in Pediatric Chronic Refractory Constipation With or Without Fecal Incontinence","Inclusion Criteria:\n\n1. Children and adolescents aged from 4 to 16 years.\n2. Participants fulfilling Rome IV criteria for the diagnosis of functional constipation.\n\n   At least 2 of the following present at least once per week for at least 1 month:\n   * 2 or fewer defecations in the toilet per week\n   * At least 1 episode of fecal incontinence per week\n   * History of retentive posturing or excessive volitional stool retention\n   * History of painful or hard bowel movements\n   * Presence of a large fecal mass in the rectum\n   * History of large-diameter stools that may obstruct the toilet The symptoms cannot be fully explained by another medical condition (Hyams et al., 2016).\n3. Participants who have chronic refractory constipation. Chronic refractory constipation (CRC) is defined as children who are unable to pass stools in spite of being on maximum laxative therapy and require daily rectal stimulation in the form of enemas or suppositories to pass stools 4-Is willing and able to keep a diary on his\u002Fher own and willing and able to complete a questionnaire.\n\n5-The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.\n\nExclusion Criteria:\n\n* participants who have anorectal malformation\n* participants who have neurological disease affecting lower limbs\n* Has a history of hypersensitivity or allergies to lubiprostone","4 Years","16 Years",{"count":182,"type":21},60,[184,185],"PHASE1","PHASE2","Anorectal manometry and high-resolution anorectal manometry (HRAM) are becoming the investigation of choice for understanding the pathophysiology of chronic constipation with or without fecal incontenance in children in many institutions. In high resolution anorectal manometery we are able to gain information whether the symptoms are related to sphincter dysfunction, impaired sensation, or pelvic floor dyssynergia",[28],"2024-10-05",{"date":190,"type":33},"2024-10-09",{"date":192,"type":33},"2024-09-07",{"date":194,"type":21},"2025-10-01",{"name":196,"class":77},"Ain Shams University",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":78},"100548966","effect-of-antibiotic-pretreatment-on-the-efficacy-of-wmt-in-the-treatment-of-chronic-constipation-100548966","NCT06427863","Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Chronic Constipation","Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Chronic Constipation in Adults: a Multi-center, Randomized, Placebo-controlled Clinical Study","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to enter the study:\n\n1. Male and female, aged ≥18 years old, provided written informed consent;\n2. Subjects diagnosed with chronic constipation, with a duration of at least 6 months, and with the following conditions:\n\n1\\) spontaneous bowel movement frequency \\\u003C3 times\u002Fweek (spontaneous bowel movement was defined as spontaneous bowel movement without rescue laxatives or manual assistance); 2) waste hard: at least 25% of defecation in Bristol stool traits scale type 1 or 2.\n\n3\\. The subjects or their legal representatives gave informed consent, fully understood the purpose of the study, were able to communicate well with the researchers, and understood and complied with the requirements of the study.\n\nExclusion Criteria:\n\nSubjects meeting any of the following exclusion criteria must be excluded fromthe study:\n\n1. Presence of outlet obstruction and constipation, such as rectal mucosal prolapse\n2. Combined with the results of colonoscopy in the past 24 months, those with intestinal stenosis caused by organic lesions of the digestive tract (such as tumor, inflammation, anal fissure, Crohn's disease, ulcerative colitis, intestinal adhesion, intestinal tuberculosis, etc.) and constipation;\n3. Constipation caused by other systemic diseases involving the digestive tract, such as nervous system diseases (such as Parkinson's disease, spinal cord injury, multiple sclerosis, etc.), muscle diseases (such as amyloidosis, dermatomyositis, etc.), mental disorders (such as depression, etc.), metabolic and endocrine disorders (such as diabetes, hypothyroidism, etc.) or opioids, etc.\n4. Has a history of abdominal pelvic surgery, but after cystic resection, cesarean section, does not appear after appendectomy postoperative intestinal complications, and intestinal polyps except after treatment;\n5. Has a history of major surgery within 3 months or a history of severe trauma, and recovery is not completely;\n6. There are contraindications to colonic transendoscopic intestinal tube implantation, such as severe intestinal stenosis, obstruction, deep ulcer, and high risk of operation perforation; Severe ulcers or a large number of pseudopolyps exist in the fixed area of titanium clips, which are not suitable for fixation. The subjects' behavior was seriously uncontrolled.\n7. Any of the following abnormalities in cardiac function and performance:\n\n   1. According to the New York Heart Association (NYHA) cardiac function classification, cardiac function grade Ⅲ or above;\n   2. new onset myocardial infarction or unstable angina pectoris within 6 months;\n   3. ECG showed QTc prolongation (QTc≥ 450ms in men and ≥470ms in women);\n   4. Drug-refractory atrial arrhythmias and drug-refractory ventricular arrhythmias (including grade 2 or higher atrioventricular block).\n8. Patients with poor lung function that is considered by the investigator to have an impact on the study treatment, such as patients with acute exacerbation of COPD or patients requiring long-term use of oral or intravenous steroids for control (except inhalers\u002Fsprays);\n9. No control autoimmune disease and\u002For need long-term use of hormone (except local external use sex);\n10. Patients with metabolic diseases and poorly controlled by drugs (such as thyroid dysfunction), or patients with metabolic diseases accompanied by gastrointestinal function complications (such as gastrointestinal autonomic nerve dysfunction, diabetic gastroparesis, etc.);\n11. Suffering from reproductive system diseases (including but not limited to ovarian cysts, endometriosis, primary dysmenorrhea, etc.) that may lead to abdominal pain;\n12. Significant laboratory abnormalities that, in the judgment of the investigator, may affect the safety of the subjects or the completion of the clinical study, including:\n\n    A) the hemoglobin \\\u003C 100 g\u002FL; B) Serum creatinine ≥1.5 times the upper limit of normal (ULN) C) abnormal liver function, defined as AST\\>1.5×ULN and\u002For ALT\\>1.5×ULN and\u002For total bilirubin \\>1.5×ULN; D) blood clotting function: PLT acuities were 80 x 109 \u002F L, APTT \\> 1.5 x ULN, PT \\> 1.5 x ULN, INR \\> 1.5 x ULN; E) abnormal results or defecate occult blood stool and has prompted the clinical significance of the gastrointestinal tract.\n13. Have active hepatitis (requiring or taking long-term treatment), HIV, or active tuberculosis;\n14. A history of drug or alcohol abuse (i.e., drinking more than 14 servings per week of beer, 45 mL of 40% spirits, or 150 mL of wine) or substance abuse;\n15. The known allergic to research similar drugs, drugs or accessories;\n16. Use of anti-infective drugs (antibiotics, antifungal, antiviral) within 14 days before enrollment, or need anti-infective treatment at enrollment evaluation;\n17. Drugs and supplements that affect gastrointestinal motility and function cannot be stopped during the study, including but not limited to: antibiotics such as erythromycin; Drugs that modulate the intestinal microecology, such as probiotics such as Bifidobacterium; The parasympathetic nerve inhibitors, some scopolamine and atropine, belladonna, etc; Muscle relaxants, such as succinylcholine; Antidiarrheal agents such as loperamide, smecta; Opioid preparations; Drugs that inhibit gastric acid secretion;\n18. Pregnant or lactating women, or refusing to use an effective contraceptive method within 3 months after the last dose of treatment;\n19. 3 months prior to dosing involved in drug interventional clinical trials;\n20. Suffering from malignant tumors;\n21. There were other circumstances that the investigator considered inappropriate for participating in the study.",{"count":205,"type":21},96,[24],"This is a randomized controlled trial to explore the efficacy of antibiotic pretreatment on the efficacy of WMT in the treatment of chronic constipation in adults: a multi-center, randomized, placebo-controlled clinical study",[28],[210,211,212,213,214],"chronic constipation","washed microbiota transplantation","antibiotic pretreatment","randomized controlled trial","transendoscopic enteral tube","2024-05-20",{"date":217,"type":33},"2024-05-24",{"date":219,"type":21},"2024-06",{"date":221,"type":21},"2029-12-31",{"name":223,"class":77},"Faming Zhang",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":230,"maxAge":49,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":232,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":78},"100348612","sacral-neuromodulation-as-treatment-for-chronic-constipation-100348612","NCT03819062","Sacral Neuromodulation as Treatment for Chronic Constipation","Inclusion Criteria:\n\n* Patients with severe chronic refractory constipation\n* Must have undergone high resolution colonic manometry that shows abnormal coordination between colonic motility and ano-rectal function.\n\nExclusion Criteria:\n\n* Pregnant patients\n* Known malignancies in the area of treatment\n* Active bleeding in area of treatment\n* Active deep vein thrombosis\n* When tatoos are present at area of treatment\n* Patients that are light sensitive\n* Patients who take NSAIDS or steroids.","6 Years",{"count":129,"type":21},[24],"The objective of this study is to study if low level laser therapy will do more good than harm for patients with severe chronic refractory constipation. It is a proof of concept study without a placebo arm.",[28],[236,237,238,239,240],"Constipation","spinal cord injury","back pain","High-Resolution Colonic Manometry","Anorectal Manometry","2022-04-04",{"date":243,"type":33},"2022-04-05",{"date":245,"type":33},"2019-09-08",{"date":247,"type":21},"2027-02-01",{"name":249,"class":77},"McMaster University"]